key: cord-0876334-lyv146r6
authors: Li, Guo-Fu; An, Xiao-Xiao; Yu, Yichao; Jiao, Li-Rong; Canarutto, Daniele; Yu, Guo; Wang, Guangji; Wu, Dan-Na; Xiao, Yin
title: Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis
date: 2020-11-10
journal: Gut
DOI: 10.1136/gutjnl-2020-323366
sha: 456e8dae7f97eac9e5912684fce8d51c6b937274
doc_id: 876334
cord_uid: lyv146r6

nan

Six (0.4%, 95% CI; 0.14%-0.86% with continuity correction) patients turned out to be COVID-19 positive within 48-72 hours of the endoscopic procedure. Of 74 HCWs, 3 (4%, 95% CI; 0.8% -t 11.4% with continuity correction) developed COVID-19 infection. The risk of a HCWs getting COVID-19 positive after using adequate PPE was 0.26% per 100 endoscopies (figure 1). None of the patients developed COVID-19 after 72 hours up to 2 weeks of endoscopy. This risk of transmission should be viewed in the context of the high transmission phase (4.5%-5.1% swab positivity rate in the community) 5 6 in India during that period

The zero risk of cross-infection in the UK study could be due to multiple reasons: (1) deceleration phase of infection, (2) 42% of patients were tested based on SCOTS criteria (telephone screen questions around Symptoms, infectious Contacts, Occupational risk, Travel risk and Shielding status) and only three turned out to be positive and (iii) adherence to infection control practices. A higher rate of infection in our study could be a reflection of communityacquired infection and not necessarily due to endoscopy. It was reassuring that none of the patients developed infection similar to the UK study. These results of both the studies highlight that the risk of transmission is minimal, despite endoscopy being an aerosol-generating procedure, although with strict adherence to infection control policies, adequate use of PPE and criteria-based preprocedure testing rather than mandatory testing as advised by some guidelines such as NICE, UK. 3 7 We concur with Hayee et al and recommend gradual resumption of outpatient diagnostics depending on local transmission phase of COVID-19 and report with safety guidance.

Provenance and peer review Not commissioned; externally peer reviewed. This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. (PPIs) increased the risk of severe clinical outcomes of COVID-19 rather than the susceptibility to SARS-CoV-2 infection in a Korean nationwide cohort. Instead, a significant association between susceptibility to SARS-CoV-2 infection and current use of PPIs, either one time or two times a day, was found by another recent study 2 based on US nationwide data. The conflicting results of these two large-scale observational studies may be due to regional epidemiological differences or considerable betweenstudy variance and might compromise clinical decision-making. As the impact of PPI use on SARS-CoV-2 infection has very relevant clinical implications, we performed a meta-analysis to address the aforementioned discrepancies, which could lead to better informed clinical decision-making on PPI use during the ongoing pandemic.

We scrutinised 3413 records retrieved from a comprehensive search using the COVID-19 Research Articles Downloadable Database maintained by the US CDC (https://www. cdc. gov/ library/ researchguides/ 2019novelcoronavirus/ researcharticles. html) and ultimately included 16 studies 1-16 from 10 countries or regions reporting comparative data on PPI use and clinical outcomes of COVID-19 (online supplemental figure  1 and table) . We pooled the data using an inverse variance-weighted random-effect model. Pooled estimates are presented as OR, HR or mean difference (MD), with associated 95% CIs. Intensive care unit admission, mechanical ventilation, acute respiratory distress syndrome or death were considered severe outcomes of COVID-19.

Six studies 1-6 including 318 261 participants reported data on PPI usage and the risk of SARS-CoV-2 infection. Among them, five studies had information of current PPI users compared with nonusers and four on past PPI users versus non-users. Analysis of five studies 1-5 encompassing 145 428 patients who were tested for SARS-CoV-2 showed that the risk of SARS-CoV-2 infection was higher, although not significantly, among current PPI users (OR 1.33, 95% CI 0.86 to 2.07, p=0.20; figure 1) compared with PPI non-users, with evidence of substantial between-study heterogeneity (I 2 =97%). Moreover, in a subgroup analysis of non-Korean cohorts, 2-4 we found a significant association between current use of PPIs and increased risk of SARS-CoV-2 infection (OR 1.94, 95% CI 1.59 to 2.36, p<0.0001; online supplemental figure 2). Furthermore, a leave-one-out sensitivity analysis revealed that the summary estimate of the association between current PPI usage and SARS-CoV-2 infection was overly influenced by a single Korean study 5 (online supplemental figure 3 ).

Instead, current or regular PPI users were more likely to have severe outcomes of COVID-19 than PPI non-users, with a pooled OR of 1.67 (95% CI 1.19 to 2.33, p=0.003; n=42 405 from nine studies; 1 3 7-13 I 2 =63%; figure 2 ) and a pooled HR of 1.87 (95% CI 1.29 to 2.70, p<0.001; n=2977 from two studies; 15 16 I 2 =80%; figure 2). These results were consistent with our leaveone-out sensitivity analysis (online supplemental figure 4) , indicating that this association was strong. Furthermore, PostScript current PPI users tended to hospitalised longer than PPI non-users, although not by a statistically significant margin (n=353 from two studies; 7 14 MD 1.13, 95% CI −0.18 to 2.43, p=0.09; figure 2 ). Finally, past use of PPIs was not associated with increased susceptibility to SARS-CoV-2 infection (n=1 72 833 from four studies; 1 3 5 6 OR 0.85, 95% CI 0.57 to 1.27, p=0.43; I 2 =92%; figure 1) or with severe outcomes of COVID-19 (n=40 097 from three studies; 1 3 9 OR 1.03, 95% CI 0.85 to 1.23, p=0.79; I 2 =0%; figure 2 ).

In summary, this meta-analysis shows that regional differences can explain the heterogeneous findings concerning the association between current PPI use and incidence of SARS-CoV-2 infection and further underscores the increased risk of severe COVID-19 outcomes associated with current PPI use, highlighting that caution should be exercised when treating patients receiving PPIs during the COVID-19 pandemic. Further studies investigating different dosing regimens and durations of PPI use on COVID-19 outcomes should be warranted.

Multicentre prospective study of COVID-19 transmission following outpatient Gi endoscopy in the UK

Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a national endoscopy database analysis

AGA rapid recommendations for gastrointestinal procedures during the COVID-19 pandemic

ESGE and ESGENA position statement on gastrointestinal endoscopy and the COVID-19 pandemic

Coronavirus in India: latest map and case count

overview | COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services | guidance | NICE

Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching

Increased risk of COVID-19 among users of proton pump inhibitors

COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: a single-centre cohort study

Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: a population-based cohort study in southern Catalonia, Spain

Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea

Are proton pump inhibitors contributing to SARS-COV-2 infection?

Prehospitalization proton pump inhibitor (PPI) use and clinical outcomes in COVID-19

Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?

Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study

Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients

Clinical characteristics of coronavirus disease

Analysis of the effect of proton pump inhibitors on the course of common COVID-19

The influence of pH on SARS-CoV-2 infection and COVID-19 severity

Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study

Patient consent for publication Not required.Provenance and peer review Not commissioned; externally peer reviewed. This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/.